Molecules engineered against oncogenic proteins and cancer /

Molecules engineered against oncogenic proteins and cancer /

Saved in:
Bibliographic Details
Main Authors: Corey, E. J. (Author), Wu, Yong-Jin (Author)
Format: Electronic eBook
Language:English
Published: Hoboken, New Jersey : John Wiley & Sons, Inc., [2024]
Subjects:
Protein-tyrosine kinase > Inhibitors > Therapeutic use.
Online Access:CONNECT
Table of Contents:
  • Cover
  • Title Page
  • Copyright
  • Contents
  • Preface
  • Chapter 1. Introduction
  • 1.1 Types of Protein Kinases
  • 1.2 Protein Kinase Domains
  • 1.3 ATP-Binding Site
  • 1.4 Types of Kinase Inhibitors
  • 1.5 Brief History of Small-molecule kinase Inhibitors
  • 1.6 Peak 12-Month Sales for Leading Kinase Inhibitors
  • 1.7 Approved Kinase Inhibitors
  • Chapter 2. BCR-ABL Inhibitors
  • 2.1 Imatinib*
  • 2.2 Nilotinib*
  • 2.3 Dasatinib*
  • 2.4 Bosutinib*
  • 2.5 Ponatinib*
  • 2.6 Olvermbatinib**
  • 2.7 Asciminib*
  • Chapter 3. BTK Inhibitors
  • 3.1 Ibrutinib*
  • 3.2 Acalabrutinib*
  • 3.3 Zanubrutinib*
  • 3.4 Tirabrutinib**
  • 3.5 Orelabrutinib**
  • Chapter 4. EGFR/HER Family Inhibitors
  • 4.1 Gefitinib*
  • 4.2 Erlotinib *
  • 4.3 Icotinib**
  • 4.4 Afatinib*
  • 4.5 Dacomitinib*
  • 4.6 Osimertinib*
  • 4.7 Mobocertinib*
  • 4.8 Lapatinib*
  • 4.9 Tucatinib*
  • 4.10 Neratinib*
  • Chapter 5. VEGFR/Multikinase Inhibitors
  • 5.1 Sorafenib*
  • 5.2 Regorafenib*
  • 5.3 Sunitinib*
  • 5.4 Pazopanib*
  • 5.5 Axitinib*
  • 5.6 Nintedanib*
  • 5.7 Apatinib**
  • 5.8 Lenvatinib*
  • 5.9 Tovozanib*
  • Chapter 6. CDK4/6 Inhibitors
  • 6.1 Palbociclib*
  • 6.2 Ribociclib*
  • 6.3 Abemaciclib*
  • 6.4 Trilaciclib*
  • Chapter 7. JAK Inhibitors
  • 7.1 Tofacitinib*
  • 7.2 Baricitinib*
  • 7.3 Peficitinib**
  • 7.4 Upadacitinib*
  • 7.5 Delgocitinib**
  • 7.6 Filgotinib**
  • 7.7 Abrocitinib*
  • 7.8 Ruxolitinib*
  • 7.9 Fedratinib*
  • 7.10 Pacritinib*
  • 7.11 Ritlecitinib#
  • 7.12 Brepocitinib#
  • 7.13 Ropsacitinib#
  • Chapter 8. Allosteric TYK2 Inhibitors
  • 8.1 Deucravacitinib*
  • Chapter 9. ALK/multikinase Inhibitors
  • 9.1 Crizotinib*
  • 9.2 Ceritinib*
  • 9.3 Alectinib*
  • 9.4 Brigatinib*
  • 9.5 Lorlatinib*
  • Chapter 10. BRAF/Multikinase Inhibitors
  • 10.1 Vemurafenib*
  • 10.2 Dabrafenib*
  • 10.3 Encorafenib*
  • Chapter 11. MEK Inhibitors
  • 11.1 Trametinib*
  • 11.2 Cobimetinib*
  • 11.3 Binimetinib*
  • 11.4 Selumetinib*
  • Chapter 12. RET/Multikinase Inhibitors
  • 12.1 Vandetanib*
  • 12.2 Cabozantinib*
  • 12.3 Selpercatinib*
  • 12.4 Pralsetinib*
  • Chapter 13. FGFR Inhibitors
  • 13.1 Erdafitinib*
  • 13.2 Pemigatinib*
  • 13.3 Infigratinib*
  • 13.4 Futibatinib*
  • Chapter 14. PI3K Inhibitors
  • 14.1 Alpelisib*
  • 14.2 Idelalisib*
  • 14.3 Duvelisib*
  • 14.4 Umbralisib*
  • 14.5 Copanlisib*
  • Chapter 15. TRK/Multikinase Inhibitors
  • 15.1 Larotrectinib*
  • 15.2 Entrectinib*
  • 15.3 Repotrectinib#
  • Chapter 16. MET Inhibitors
  • 16.1 Capmatinib*
  • 16.2 Tepotinib*
  • Chapter 17. KIT/PDGFR/Multkinase Inhibitors
  • 17.1 Avapritinib*
  • 17.2 Ripretinib*
  • Chapter 18. FLT3 Inhibitors
  • 18.1 Midostaurin*
  • 18.2 Gilteritinib*
  • Chapter 19. mTOR Inhibitors
  • 19.1 Sirolimus* and Analogs
  • Chapter 20. Other Kinase Inhibitors
  • 20.1 Netarsudil*
  • 20.2 Belumosudil*
  • 20.3 Fostamatinib*
  • 20.4 Pexidartinib*
  • Chapter 21. KRAS Inhibitors
  • 21.1 Sotorasib*
  • 21.2 Adagrasib*
  • 21.3 JDQ443#

Similar Items